Abstract
Mitochondria are cytoplasmic organelles responsible for life and death. Extensive evidence from animal models, postmortem brain studies of and clinical studies of aging and neurodegenerative diseases suggests that mitochondrial function is defective in aging and neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, Huntingtons disease, and amyotrophic lateral sclerosis. Several lines of research suggest that mitochondrial abnormalities, including defects in oxidative phosphorylation, increased accumulation of mitochondrial DNA defects, impaired calcium influx, accumulation of mutant proteins in mitochondria, and mitochondrial membrane potential dissipation are important cellular changes in both early and late-onset neurodegenerative diseases. Further, emerging evidence suggests that structural changes in mitochondria, including increased mitochondrial fragmentation and decreased mitochondrial fusion, are critical factors associated with mitochondrial dysfunction and cell death in aging and neurodegenerative diseases. This paper discusses research that elucidates features of mitochondria that are associated with cellular dysfunction in aging and neurodegenerative diseases and discusses mitochondrial structural and functional changes, and abnormal mitochondrial dynamics in neurodegenerative diseases. It also outlines mitochondria-targeted therapeutics in neurodegenerative diseases.
Keywords: Abnormal mitochondrial dynamics, aging, Alzheimer's disease, Huntington's disease, mitochondria, mitochondriatargeted antioxidants, neurodegenerative disease, Parkinson's disease, amyotrophic lateral sclerosis, mitochondrial matrix, mtDNA
Current Alzheimer Research
Title: Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Volume: 8 Issue: 4
Author(s): P. H. Reddy and T. P. Reddy
Affiliation:
Keywords: Abnormal mitochondrial dynamics, aging, Alzheimer's disease, Huntington's disease, mitochondria, mitochondriatargeted antioxidants, neurodegenerative disease, Parkinson's disease, amyotrophic lateral sclerosis, mitochondrial matrix, mtDNA
Abstract: Mitochondria are cytoplasmic organelles responsible for life and death. Extensive evidence from animal models, postmortem brain studies of and clinical studies of aging and neurodegenerative diseases suggests that mitochondrial function is defective in aging and neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, Huntingtons disease, and amyotrophic lateral sclerosis. Several lines of research suggest that mitochondrial abnormalities, including defects in oxidative phosphorylation, increased accumulation of mitochondrial DNA defects, impaired calcium influx, accumulation of mutant proteins in mitochondria, and mitochondrial membrane potential dissipation are important cellular changes in both early and late-onset neurodegenerative diseases. Further, emerging evidence suggests that structural changes in mitochondria, including increased mitochondrial fragmentation and decreased mitochondrial fusion, are critical factors associated with mitochondrial dysfunction and cell death in aging and neurodegenerative diseases. This paper discusses research that elucidates features of mitochondria that are associated with cellular dysfunction in aging and neurodegenerative diseases and discusses mitochondrial structural and functional changes, and abnormal mitochondrial dynamics in neurodegenerative diseases. It also outlines mitochondria-targeted therapeutics in neurodegenerative diseases.
Export Options
About this article
Cite this article as:
H. Reddy P. and P. Reddy T., Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases, Current Alzheimer Research 2011; 8 (4) . https://dx.doi.org/10.2174/156720511795745401
| DOI https://dx.doi.org/10.2174/156720511795745401 |
Print ISSN 1567-2050 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Blood Tests: Advancements and the Future of Point-of-Care
The recent FDA approval of lecanemab (Leqembi), the first treatment for Alzheimer’s disease targeting early stages and mild cognitive impairment, has brought renewed hope for the therapeutic future of this devastating condition. While the exact causes and mechanisms of Alzheimer’s disease remain obscure, there is an urgent consensus on the ...read more
Atypical Alzheimer’s disease: towards inclusion into disease-modifying clinical trials
Patients with non-amnestic atypical variants of Alzheimer’s disease show considerable heterogeneity in clinical characteristics, including visual, language and behavioral impairments, and often have a young age onset. Current clinical trials for anti-amyloid therapies do not sufficiently account for this heterogeneity, and it is unclear whether current treatments tested in amnestic ...read more
Drug Discovery and Possible Therapeutic Developments in Neurological Disorders Alzheimer’s Disease and Tauopathy
A critical appraisal Alzheimer's disease (AD) is a devastating mental illness in society and the etiology and pathogenesis of AD are still poorly understood. One of the key hallmark pathological proteins of AD is tau, where the pathophysiology and the functional relationships between hyperphosphorylation of tau and synaptic damage in ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design RNA Metabolism in Neurodegenerative Disease
Current Chemical Biology tiRNAs & tRFs Biogenesis and Regulation of Diseases: A Review
Current Medicinal Chemistry Phosphorylation-Dephosphorylation Imbalance of Cytoskeletal Associated Proteins in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Neuroprotection by Polyphenols
Current Medicinal Chemistry - Central Nervous System Agents Anti-aging Natural Compounds and their Role in the Regulation of Metabolic Pathways Leading to Longevity
Mini-Reviews in Medicinal Chemistry Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology Commentary: Histaminergic Drugs Could be Novel Targets for Neuroprotection in CNS Disorders
CNS & Neurological Disorders - Drug Targets NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Tau Therapeutic Strategies for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Bioinformatics and Protein Design
Current Pharmaceutical Biotechnology Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
Current Pharmaceutical Design Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Does Ceruloplasmin Defend Against Neurodegenerative Diseases?
Current Neuropharmacology Modelling and Treating Amyotrophic Lateral Sclerosis through Induced- Pluripotent Stem Cells Technology
Current Stem Cell Research & Therapy Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry





